Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/125705
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ghosh, Nilanjan | - |
dc.contributor.author | Karmali, Reem | - |
dc.contributor.author | Rocha, Vanderson | - |
dc.contributor.author | Ahn, Kwang Woo | - |
dc.contributor.author | Digilio, Alyssa | - |
dc.contributor.author | Hari, Parameswaran | - |
dc.contributor.author | Bachanova, Veronika | - |
dc.contributor.author | Bacher, Ulrike | - |
dc.contributor.author | Dahi, Parastoo B. | - |
dc.contributor.author | Lima, Marcos de | - |
dc.contributor.author | D'Souza, Anita | - |
dc.contributor.author | Fenske, Timothy S. | - |
dc.contributor.author | Ganguly, Siddhartha | - |
dc.contributor.author | Kharfan-Dabaja, Mohamed A. | - |
dc.contributor.author | Prestidge, Tim D. | - |
dc.contributor.author | Savani, Bipin N. | - |
dc.contributor.author | Smith, Sonali M. | - |
dc.contributor.author | Sureda, Anna | - |
dc.contributor.author | Waller, Edmund K. | - |
dc.contributor.author | Jaglowski, Samantha | - |
dc.contributor.author | Herrera, Alex F. | - |
dc.contributor.author | Armand, Philippe | - |
dc.contributor.author | Salit, Rachel B. | - |
dc.contributor.author | Wagner-Johnston, Nina D. | - |
dc.contributor.author | Fuchs, Ephraim | - |
dc.contributor.author | Bolanos-Meade, Javier | - |
dc.contributor.author | Hamadani, Mehdi | - |
dc.date.accessioned | 2018-10-29T14:29:24Z | - |
dc.date.available | 2018-10-29T14:29:24Z | - |
dc.date.issued | 2016-09-10 | - |
dc.identifier.uri | http://hdl.handle.net/2445/125705 | - |
dc.description.abstract | Purpose: Related donor haploidentical hematopoietic cell transplantation (Haplo-HCT) using post-transplantation cyclophosphamide (PT-Cy) is increasingly used in patients lacking HLA-matched sibling donors (MSD). We compared outcomes after Haplo-HCT using PT-Cy with MSD-HCT in patients with lymphoma, using the Center for International Blood and Marrow Transplant Research registry. Materials and Methods: We evaluated 987 adult patients undergoing either Haplo-HCT (n = 180) or MSD-HCT (n = 807) following reduced-intensity conditioning regimens. The haploidentical group received graft-versus-host disease (GVHD) prophylaxis with PT-Cy with or without a calcineurin inhibitor and mycophenolate. The MSD group received calcineurin inhibitor-based GVHD prophylaxis. Results: Median follow-up of survivors was 3 years. The 28-day neutrophil recovery was similar in the two groups (95% v 97%; P = .31). The 28-day platelet recovery was delayed in the haploidentical group compared with the MSD group (63% v 91%; P = .001). Cumulative incidence of grade II to IV acute GVHD at day 100 was similar between the two groups (27% v 25%; P = .84). Cumulative incidence of chronic GVHD at 1 year was significantly lower after Haplo-HCT (12% v 45%; P < .001), and this benefit was confirmed on multivariate analysis (relative risk, 0.21; 95% CI, 0.14 to 0.31; P < .001). For Haplo-HCT v MSD-HCT, 3-year rates of nonrelapse mortality (15% v 13%; P = .41), relapse/progression (37% v 40%; P = .51), progression-free survival (48% v 48%; P = .96), and overall survival (61% v 62%; P = .82) were similar. Multivariate analysis showed no significant difference between Haplo-HCT and MSD-HCT in terms of nonrelapse mortality (P = .06), progression/relapse (P = .10), progression-free survival (P = .83), and overall survival (P = .34). Conclusion: Haplo-HCT with PT-Cy provides survival outcomes comparable to MSD-HCT, with a significantly lower risk of chronic GVHD. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1200/JCO.2015.66.3476 | - |
dc.relation.ispartof | Journal of Clinical Oncology, 2016, vol. 34, num. 26, Pp 3141-3149 | - |
dc.relation.uri | https://doi.org/10.1200/JCO.2015.66.3476 | - |
dc.rights | (c) American Society of Clinical Oncology, 2016 | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Limfomes | - |
dc.subject.classification | Ciclofosfamida | - |
dc.subject.other | Lymphomas | - |
dc.subject.other | Cyclophosphamide | - |
dc.title | Reduced-intensity Transplantation For Lymphomas Using Haploidentical Related Donors Versus Hla-matched Sibling Donors: A Center For International Blood And Marrow Transplant Research Analysis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2018-07-24T12:17:20Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 27269951 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
GhoshN.pdf | 633.32 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.